Important information for our community: | |||
| COVID-19 Resource Center | Your Care During the Pandemic | ||
About Holy Name Medical Center201-833-3000
877-HOLY-NAME (465-9626)
201-833-3300
201-833-3187
201-833-7040
201-833-3352
For general questions or comments, email info@holyname.org
Learn more about these studies:
|
|
|
List of Clinical Studies |
|
| Gynecologic Oncology - Cervical Cancer | |
| Study Name | Principal Investigator |
 |
|
|
MK3475-826 – A phase 3 randomized, double-blind, placebo-controlled study of Pembrolizumab (MK3475) plus chemotherapy vs. chemotherapy plus placebo for the first-line treatment of persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826). Read more. |
Sharyn Lewin, MD |
|
|
| Gynecologic Oncology - Endometrial Cancer | |
| Study Name | Principal Investigator |
|
|
|
MK7902-001 – A Multicenter, Open-label, Randomized Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician’s Choice in Participants with Advanced Endometrial Cancer. Hypothesis is that combination therapy leads to improved progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|
|
MK3475-775 – A Phase 3 Randomized, Open-label, Study of Pembrolizumab (MK-3475) Plus Levantinib versus Chemotherapy for First-Line Treatment of Advanced or Recurrent Endometrial Carcinoma. Hypothesis is that the combination for pembrolizumab plus Levantinib is superior to chemotherapy with respect to progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|
|
GOG-3039 – A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced,
Recurrent or Metastatic Endometroid Endometrial Cancer. Read more. |
Sharyn Lewin, MD |
|
|
| Gynecologic Oncology - Mixed Cancer Indication | |
| Study Name | Principal Investigator |
|
|
|
MIRASOL – A randomized, open-label, phase 3 study of Mirvetuximab Soravtansine vs. investigator's choice of chemotherapy in advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. Read more. |
Sharyn Lewin, MD |
|
|
|
LIGHT – Non-randomized, open-label phase 2 study to assess Olaparib tablets as a treatment for subjects with different HRD tumors status and with platinum-sensitive, relapsed, high-grade serous or high-grade endometrial, ovarian, fallopian tube, or primary peritoneal cancer that have received at least 1 prior line of chemotherapy. Read more. |
Sharyn Lewin, MD |
|
|
|
IMAGYN050 – A phase 2, multicenter, randomized, placebo-controlled study of Atezolizumab vs. placebo in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly diagnosed stage iii/iv ovarian, fallopian tube, or primary peritoneal cancer. Read more. |
Sharyn Lewin, MD |
|
|
| Gynecologic Oncology - Ovarian Cancer | |
| Study Name | Principal Investigator |
|
|
|
FIRST – A Randomized, double-Blind, Phase 3 Comparison of Platinum-Based Therapy with TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-line treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer. Hypothesis is that TSR-042 and Niraparib produces a deeper response and prolonged progression-free survival. Read more. |
Sharyn Lewin, MD |
|
|
|
MK7339-001 – A randomized phase 3, double-blind study of chemotherapy with or without Pembrolizumab followed by maintenance with Olaparib or placebo for the first-line treatment of BRCA non-mutated advanced epithelial ovarian cancer. Read more. |
Maria Schiavone, MD |
|
|
|
AZ DUETTE – A Phase 2 Randomized, Multi-Centre Study to Investigate the Efficacy and
Tolerability of a Second Maintenance Treatment in Patients With Platinum Sensitive Relapsed
Epithelial Ovarian Cancer, Who Have Previously Received PARP Inhibitor Maintenance
Treatment Read more. |
Sharyn Lewin, MD |
|
|
|
AZ DUO-E – A Randomized, Multicentre, Double-blind, Placebo-controlled, Phase III Study of
First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance
Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent
Endometrial Cancer Read more. |
Maria Schiavone, MD |
|
|
